Schaus; John Mehnert

Patent Applications and Registrations

Patent applications and USPTO patent grants for Schaus; John Mehnert.The latest application filed is for "3,4-dihydroisoquinolin-2(1h)-yl compounds".

Company Profile

0.20.17

Schaus; John Mehnert - Indianapolis IN
Schaus; John Mehnert - Zionsville IN US

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
3,4-dihydroisoquinolin-2(1H)-yl compounds Grant 8,962,654 - Beadle , et al. February 24, 2	2015-02-24
3,4-dihydroisoquinolin-2(1h)-yl Compounds App 20140357664 - BEADLE; Christopher David ; et al.	2014-12-04
1,5-Diphenyl-pyrrolidin-2-one compounds as CB-1 ligands Grant 8,420,654 - Schaus April 16, 2	2013-04-16
Inhibitors of diacylglycerol acyltransferase Grant 8,299,061 - Arnold , et al. October 30, 2	2012-10-30
2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines as 5-HT7 receptor antagonists Grant 8,202,873 - Badescu , et al. June 19, 2	2012-06-19
1, 5-diphenyl-3-benzylamino-1, 5-dihydropyrrolidin-2-one as CB1 receptor modulators Grant 8,168,659 - Coffey , et al. May 1, 2	2012-05-01
N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor Grant 8,044,090 - Chen , et al. October 25, 2	2011-10-25
1,5-diphenyl-3-pyridinylamino-1,5-dihydropyrrolidin-2-one as CB1 receptor modulator Grant 7,998,985 - Schaus August 16, 2	2011-08-16
Inhibitors of Diacylglycerol Acyltransferase App 20110144091 - Arnold; Macklin Brian ; et al.	2011-06-16
1,5-diphenyl-pyrrolidin-2-one Compounds As Cb-1 Ligands App 20110034484 - Schaus; John Mehnert	2011-02-10
2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl Pyrazines And Pyridines And 3-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-2-phenyl Pyridines As 5-ht7 Receptor Antagonists App 20100120785 - Badescu; Valentina O. ; et al.	2010-05-13
1,5-diphenyl-3-pyridinylamino-1,5-dihydropyrrolidin-2-one As Cb1 Receptor Modulator App 20100016375 - Schaus; John Mehnert ; et al.	2010-01-21
N-(2-arylethyl)benzylamines As Antagonists Of The 5-ht6 Receptor App 20090306110 - Chen; Zhaogen ; et al.	2009-12-10
1, 5-diphenyl-3-benzylamino-1, 5-dihydropyrrolidin-2-one As Cb1 Receptor Modulators App 20090275618 - Coffey; David Scott ; et al.	2009-11-05
Piperazine substituted aryl benzodiazepines Grant 7,384,934 - Aicher , et al. June 10, 2	2008-06-10
Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses Grant 7,314,937 - Beavers , et al. January 1, 2	2008-01-01
Benzenesulfonic Acid Indol-5-yl Esters As Antagonists Of The 5-ht6 Receptor App 20070135484 - Filla; Sandra Ann ; et al.	2007-06-14
Benzenesulfonic acid indol-5-yl esters as antagonists of the 5ht.sub.6 receptor Grant 7,230,011 - Filla , et al. June 12, 2	2007-06-12
Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders Grant 7,214,673 - Aicher , et al. May 8, 2	2007-05-08
N-(2-arylethyl)benzylamines As Antagonists Of The 5-ht6 Receptor App 20070099909 - Chen; Zhaogen ; et al.	2007-05-03
N-(2-Arylethyl) benzylamines as antagonists of the 5-HT.sub.6 receptor Grant 7,157,488 - Chen , et al. January 2, 2	2007-01-02
Substituted piperazines of azepines, oxazepines and thiazepines App 20060270656 - He; John Xiaoqiang ; et al.	2006-11-30
Piperazine substituted aryl benzodiazepines App 20060084643 - Aicher; Thomas Daniel ; et al.	2006-04-20
N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor App 20060009511 - Chen; Zhaogen ; et al.	2006-01-12
Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders App 20050203296 - Aicher, Thomas Daniel ; et al.	2005-09-15
1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl) piperazine and pharmaceutically acceptable salts and solvents thereof Grant 6,864,262 - Schaus , et al. March 8, 2	2005-03-08
5-HT1f agonist Grant 6,777,428 - Krushinski, Jr. , et al. August 17, 2	2004-08-17
N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor App 20040132800 - Chen, Zhaogen ; et al.	2004-07-08
Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses App 20040110748 - Beavers, Lisa Selsam ; et al.	2004-06-10
Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor App 20040102481 - Filla, Sandra Ann ; et al.	2004-05-27
1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl) piperazine and pharmaceutically acceptable salts and solvents thereof App 20040067962 - Schaus, John Mehnert ; et al.	2004-04-08
Indole derivatives and their use as 5-HT1F agonists Grant 6,608,079 - Schaus , et al. August 19, 2	2003-08-19
5-HT.sub.1F agonists Grant 6,133,290 - Krushinski, Jr. , et al. October 17, 2	2000-10-17
5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)-and 3-(piperidin-4-yl)-1h-indoles: 5-HT.sub.1F agonists Grant 5,962,474 - Audia , et al. October 5, 1	1999-10-05
5-HT.sub.1F agonists Grant 5,817,671 - Filla , et al. October 6, 1	1998-10-06
5-Substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)-and 3-(piperidin-4-yl)-1H-indoles: new 5-HT.sub.1F agonists Grant 5,708,008 - Audia , et al. January 13, 1	1998-01-13

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.